These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 84130)

  • 1. Immunoprecipitation and opsonic cross-reaction between type-14 pneumococcus and group-B streptococcus type III.
    Fischer GW; Lowell GH; Crumrine MH; Wilson SR
    Lancet; 1979 Jan; 1(8107):75-7. PubMed ID: 84130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
    Fischer GW; Lowell GH; Crumrine MH; Bass JW
    J Exp Med; 1978 Sep; 148(3):776-86. PubMed ID: 29937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunodeterminant specificity of human immunity to type III group B streptococcus.
    Kasper DL; Baker CJ; Baltimore RS; Crabb JH; Schiffman G; Jennings HJ
    J Exp Med; 1979 Feb; 149(2):327-39. PubMed ID: 84042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opsonic antibody response of female rats to type III group B streptococcal immunization: a model for maternal immunity.
    Heiman HS; Weisman LE
    Vet Immunol Immunopathol; 1990 Jan; 24(1):79-89. PubMed ID: 2180204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of bacterial carbohydrate-specific cold agglutinin antibody production with immunization by group C, group B type III, and Streptococcus pneumoniae type XIV streptococcal vaccines.
    Colling RG; Pearson TC; Brown JC
    Infect Immun; 1983 Jul; 41(1):205-13. PubMed ID: 6345390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus.
    De Cueninck BJ; Eisenstein TK; McIntosh TS; Shockman GD; Swenson RM
    Infect Immun; 1983 Mar; 39(3):1155-60. PubMed ID: 6341229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.
    Edwards MS; Baker CJ; Kasper DL
    J Infect Dis; 1979 Dec; 140(6):1004-8. PubMed ID: 396335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
    Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response to group B streptococcus type III and AB blood group antigens induced by pneumococcal vaccine.
    Boyer KM; Theeravuthichai J; Vogel LC; Orlina A; Gotoff SP
    J Pediatr; 1981 Mar; 98(3):374-8. PubMed ID: 7009817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The opsonic activity of whey and sera from heifers experimentally infected with Streptococcus agalactiae.
    Mackie DP; Pollock DA; Logan EF
    Br Vet J; 1985; 141(4):349-54. PubMed ID: 3896387
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.
    DeVelasco EA; Dekker HA; Antal P; Jalink KP; van Strijp JA; Verheul AF; Verhoef J; Snippe H
    Vaccine; 1994 Nov; 12(15):1419-22. PubMed ID: 7887020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection.
    Baker CJ; Rench MA; Kasper DL
    N Engl J Med; 1990 Jun; 322(26):1857-60. PubMed ID: 2190087
    [No Abstract]   [Full Text] [Related]  

  • 15. Cross-reacting opsonic antibodies to clinically important pneumococcal serotypes after pneumococcal vaccination.
    Braconier JH; Myhre EB; Odeberg H
    Eur J Clin Microbiol; 1983 Oct; 2(5):453-8. PubMed ID: 6641723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease.
    Givner LB; Baker CJ
    J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice.
    Alonso De Velasco E; Dekker BA; Verheul AF; Feldman RG; Verhoef J; Snippe H
    J Infect Dis; 1995 Aug; 172(2):562-5. PubMed ID: 7622906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The detection of streptococcal antigens using monoclonal antibodies.
    Harris MC; Polin RA
    Clin Lab Med; 1985 Sep; 5(3):545-60. PubMed ID: 3899481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemical cross-reactions between type III group B Streptococcus and type 14 Streptococcus pneumoniae.
    Crumrine MH; Fischer GW; Balk MW
    Infect Immun; 1979 Sep; 25(3):960-3. PubMed ID: 40876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.